BioSpace

FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues

Despite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.

By BioSpace

1 min read
FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights